Browsing by Author "Majcan, Predrag (55826837300)"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
- Some of the metrics are blocked by yourconsent settings
Publication Identification of psoriatic patients at risk of high quality of life impairment(2013) ;Sojevic̈ Timotijevic̈, Zorica (55901969300) ;Jankovic̈, Slavenka (7101906308) ;Trajkovic̈, Goran (9739203200) ;Majcan, Predrag (55826837300) ;Perišic̈, Svetlana (6603088396) ;Dostanic̈, Nenad (6506032607) ;Janic̈ijevic̈ Hudomal, Snežana (24830210700)Jankovic̈, Janko (15022715100)Psoriasis is a systematic chronic disease with large influence on patients' quality of life (QoL). The aim of this study was to assess the QoL of patients with psoriasis using generic, dermatology-specific and psoriasis-specific instruments simultaneously, to investigate the relationships between dimensions or subscales of the questionnaires and to identify categories of patients at risk of a high QoL impairment. The study comprised 100 consecutive patients with psoriasis treated at the Department of Dermatology, Clinical Center "Zvezdara", Belgrade, from January to December 2011. Three QoL questionnaires were administered: the EuroQol-5D (EQ-5D), the Dermatological Life Quality Index (DLQI) and the Psoriasis Disability Index (PDI). The Psoriasis Area and Severity Index was used in evaluating disease severity. According to our results the QoL of psoriatic patients was impaired (the overall DLQI and PDI scores were 10.5 ± 7.2 and 13.4 ± 8.7, respectively, while EQ visual analog scale score was 48.8 ± 25.1). The most predictive factor of QoL impairment was disease severity, followed by sole and nail involvement. Psoriatic arthritis and bleeding were also associated with impaired QoL. Significant correlations between the instruments used in this study were in the expected directions. Mainly strong and moderate significant correlations ranging 0.26-0.84 were seen between DLQI and PDI instruments. A detailed approach to QoL assessment may give to the dermatologist useful information that could be of help in identifying patients belonging to categories at risk of high QoL impairment due to psoriasis, thus guiding them in clinical practice. © 2013 Japanese Dermatological Association. - Some of the metrics are blocked by yourconsent settings
Publication The impact of changes in psoriasis area and severity index by body region on quality of life in patients with psoriasis(2017) ;Sojević Timotijević, Zorica (55901969300) ;Majcan, Predrag (55826837300) ;Trajković, Goran (9739203200) ;Relić, Milijana (55484461500) ;Novaković, Tatjana (24352838100) ;Mirković, Momčilo (37048783100) ;Djurić, Sladjana (37048654200) ;Nikolić, Simon (56111872000) ;Lazić, Bratislav (57193686011)Janković, Slavenka (7101906308)Psoriasis severity varies by body region, with each affected region having a different impact on patient quality of life (QoL). The aim of this study was to assess the impact of changes in the Psoriasis Area and Severity Index (PASI) scores by body region on QoL in patients with psoriasis after treatment. A total of 100 patients with psoriasis were recruited to the study. All patients completed the generic EuroQol-5D instrument and two specific QoL measures, Dermatology Life Quality Index (DLQI) and Psoriasis Disability Index (PDI) at the beginning of the study, and 50 patients successfully completed the same questionnaires four weeks after the end of the treatment. Clinical severity was assessed using PASI total score and PASI body region (head, trunk, arms, and legs) scores. QoL improved after treatment, and PASI improvements on visible body regions (head, legs, and arms) showed significant correlation with the most sub-areas of the Visual Analog Scale (EQ VAS), DLQI, and PDI. Multiple linear regression analysis revealed that PASI improvement (particularly on the head), sex, age, and disease duration were predictors of QoL score changes for most domains of the three instruments. Improvement of psoriasis in visible body regions has an appreciable influence on QoL improvement, and may positively affect treatment success in patients with psoriasis. © 2017, Croatian Dermatovenerological Society. All rights reserved.
